drugset
Drugs / Core-g28v2 60mer mRNA Vaccine
last change Jul 2024 re-read 3 minutes ago

Core-g28v2 60mer mRNA Vaccine

also known as mRNA-1644v2-Core

Messenger RNA (mRNA)

Developed for
HIV infectious disease
Investigated by
Emory University · Fred Hutchinson Cancer Center · George Washington University · International AIDS Vaccine Initiative · ModernaTX, Inc. · The University of Texas Health Science Center at San Antonio

Trials 1

today NCT05001373 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05001373 Nov 2021 → Jun 2023 HIV infectious disease International AIDS Vaccine Initiative Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Core-g28v2 60mer mRNA Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT05001373 ↗
Known as mRNA-1644v2-Core “Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)” NCT05001373 ↗
Modality Messenger RNA (mRNA) “Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)” NCT05001373 ↗
Route Intramuscular “100µg, Intramuscularly” NCT05001373 ↗